<DOC>
	<DOC>NCT00365560</DOC>
	<brief_summary>The primary objective of this study is to examine efficacy and safety of tiotropium compared to plac ebo as add-on therapy in severe asthmatics according to GINA step 4 classification</brief_summary>
	<brief_title>An Efficacy and Safety Evaluation of Tiotropium add-on Therapy in Patients With Severe Persistent Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>Outpatients of either sex, age 18 75 years, with at least a documented 5 year history of asthma, and a current diagnosis of severe, persistent asthma (GINA step 4), smoking history &lt; 10 pack years and &gt;= 1 year smoking cessation; Patients must be symptomatic Patients with a recent history (i.e., six months or less) of myocardial infarction, who have been hospitalized for heart failure (NYHA class III or IV) within the past year, with any unstable or life threatening cardiac arrhythmia or cardiac arrhythmia requiring intervention or a change in drug therapy within the past year, with malignancy for which the patient has undergone resection, radiation ther apy or chemotherapy within the last five years, who have undergone thoracotomy with pulmonary resection, with moderate to severe renal impairment (creatinine clearance = 50 mL/min)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>